SCHEDULE: Millennium Entities Report Jasper Therapeutics Stake

Millennium Management and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of Jasper Therapeutics, Inc. common stock.

Summary

• This filing is a Schedule 13G, indicating that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are reporting their beneficial ownership of Jasper Therapeutics, Inc. Voting Common Stock.
• The reporting entities collectively hold 486,454 shares through Integrated Core Strategies (US) LLC and 486,933 shares through Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.
• These holdings represent approximately 1.7% of the class of securities for each reporting entity.
• The filing confirms that these securities were not acquired or held for the purpose of influencing the control of Jasper Therapeutics, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain new strategic information or financial performance data.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing is a standard disclosure for institutional investors crossing certain ownership thresholds in publicly traded companies. It signifies a passive investment approach rather than an attempt to gain control.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant institutional ownership, which can be a factor in market perception. The passive nature of the filing suggests no immediate intent to influence corporate control.
• Management of Jasper Therapeutics: The filing informs the company's management about the holdings of major institutional investors.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Jasper Therapeutics, Millennium Management, Integrated Core Strategies, Securities Filing, Common Stock